新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 医药产业 » 罗氏支付5.95亿美元获得Chiasma三期临床罕见病药物Octreolin

罗氏支付5.95亿美元获得Chiasma三期临床罕见病药物Octreolin

来源:生物谷 2013-02-19 10:09

2013年2月19日讯 /生物谷BIOON/ -- 罗氏已获得Chiasma公司用于治疗肢端肥大症的三期临床药物Octreolin的全球商业权利,为此罗氏需支付6500万美元的预付款和5.3亿美元的里程碑付款,以获得这个药物的市场权利。

Octreolin是一种治疗肢端肥大症的口服疗法,或可取代不便利的注射疗法。现在,诺华的Sandostatin是治疗该种疾病的标准疗法,但如果Octreolin三期临床顺利,罗氏将有望与诺华展开竞争,但是诺华也已报道了其治疗肢端肥大症的库兴氏病药物Signifor乐观的结果。

Chiasma是一家以色列的生物技术公司,去年夏天,它还获得了3850万美元投资以开发Octreolin。(生物谷Bioon.com)

英文原文报道:

Roche ($RHHBY) has tied up the worldwide commercial rights to Chiasma's Phase III drug for acromegaly, a rare and progressive disease caused by the over-production of growth hormone. The pharma giant paid $65 million upfront and promised up to $530 million more in milestones in order to nail down marketing rights to the oral drug. In the pact, Genentech will take over U.S. marketing if the FDA approves the treatment.

The pact is a high-profile coup for Chiasma, which has been advancing oral drugs on a platform designed to produce new therapies that can replace inconvenient injectables. If the Phase III study is positive, Roche would be positioned to take an oral drug up against Novartis' ($NVS) Sandostatin, the current standard of care. But Novartis has also reported upbeat results for Signifor, its Cushing's disease drug, for acromegaly.

Just last summer Chiasma, an Israeli biotech technically based in the U.S., raised $38.5 million in a Series D designed to push Octreolin through the last stage of testing. Phase III is due to wrap up in the second quarter of this year. Abingworth and MPM Capital led the round, with additional cash from 7 Med Health Ventures, Arch Venture Partners, F3 Ventures, and Fredric Price, Chiasma's chair and CEO.

"If approved, Octreolin would be an important alternative for patients with acromegaly, a disorder that develops when a person's pituitary gland produces too much growth hormone," says Hal Barron, the worldwide development chief for Roche/Genentech. "Octreolin is an investigational oral regimen that avoids the painful injections of current treatment options."

Chiasma won orphan drug status at the FDA and is planning a similar move in Europe. Its technology coats small molecules in a way that prevents them from being absorbed in the digestive system, giving the active ingredient a shot at entering the bloodstream. In an interview with Globes last year, company officials said that the acromegaly market as a whole is worth about $500 million with a potential to expand its potential with an approval for neuroendocrine tumors, which is worth about $600 million.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库